Original ResearchPublished 7 May 2026Global pharmacovigilance reporting: comparative analysis of adverse event obligations across five major regulatory authoritiesCarlos G. Bernaus · Maria Lilia BournissenFrontiers in Drug Safety and Regulationdoi 10.3389/fdsfr.2026.1821686
Original ResearchPublished 9 January 2026Hepatobiliary adverse drug reactions during treatment with olaparib: an analysis of data from the EudraVigilance reporting systemElena-Mirabela Velişcu · Cecilia Cagnotta · Maria Giuseppa Sullo · Antonietta Anatriello · Francesco Salvo · Cristina ScavoneFrontiers in Drug Safety and Regulationdoi 10.3389/fdsfr.2025.1736759
ReviewPublished 1 December 2025The use of observed-to-expected analyses as a signal detection tool in COVID-19 vaccine safety surveillance: lessons learned from an industry perspectiveLaurence Serradell · Antonella Fretta · Jenny Nachbar · Jill Dreyfus · Diana Garofalo · Arianna Lucini · Susan Mather · Daina Esposito · Anne-Laure Chabanon · Vincent Bauchau · Sarah SellersFrontiers in Drug Safety and Regulationdoi 10.3389/fdsfr.2025.1650992
Drug Safety and RegulationPublished 15 August 2025A national pharmacovigilance centre perspective on pandemic preparedness - lessons learned from the COVID-19 pandemicFlorence van Hunsel · Agnes KantFrontiers in Drug Safety and Regulationdoi 10.3389/fdsfr.2025.1644680
